BioRestorative Therapies (NASDAQ:BRTX) announced new preliminary 26–52 week blinded data from the first 10 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing Phase 2 clinical trial of BRTX-100...
Search results for - BRTX
BioRestorative to unveil key Phase 2 findings on BRTX-100 for cLDD at ORS PSRS International Spine Research Symposium
BioRestorative Therapies (NASDAQ: BRTX) has announced that new preliminary 26- to 52-week blinded data from the Phase 2 clinical trial of BRTX-100 in patients with chronic lumbar disc disease (cLDD) will be presented at...
BioRestorative expands IP protecting ThermoStem cell-based metabolic disease therapy program
BioRestorative Therapies (NASDAQ:BRTX) has announced that the Israel Patent Office has issued a Notice of Allowance for a new patent application, covering several fundamental elements of its allogeneic, off-the-shelf...
BioRestorative’s IFATS presentation features ThermoStem’s potential to deliver a superior efficacy and tolerability profile over GLP-1 drugs
BioRestorative Therapies (NASDAQ:BTRX) presented advancements in its metabolic program, ThermoStem, targeting obesity and metabolic disorders, at the 21st Annual International Federation for Adipose Therapeutics and...
BioResorative’s Chief Scientist named section editor of top-tier Journal of Translational Medicine
BioRestorative Therapies (NASDAQ:BTRX) announced that Francisco Silva, the company’s chief scientist and vice president of research and development, has been appointed section editor of the newly launched Regenerative...
Rodman & Renshaw starts BioRestorative Therapies at buy; PT $15
Rodman & Renshaw launched coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $15 target price. The stock closed at $2.02 on June 26. BioRestorative develops therapeutic products using cell...
BioRestorative Therapies gains media attention for key regenerative medicine programs
Benzinga editor, Tony Noto, interviewed Lance Alstodt, BioRestorative’s (NASDAQ:BRTX) Chief Executive Officer, about the company’s two core clinical development programs (BRTX-100 targeting disc/spine disease and...
BioRestorative in substantive discussions with prospective licensing partner for ThermoStem metabolic disease program
BioRestorative Therapies (NASDAQ:BRTX) reports that it is engaged in substantive discussions with an undisclosed commercial stage regenerative medicine company concerning the licensing of its proprietary off-the-shelf...
BioRestorative Therapies and Cartessa Aesthetics collaborate to build a vertically integrated, best-in-class biocosmeceutical platform
BioRestorative Therapies (NASDAQ:BRTX) announced that it has entered into a five-year exclusive supply agreement with Cartessa Aesthetics. The goal of this transformative agreement is to combine BioRestorative’s deep...
BioRestorative Therapies propelling cell-based therapies for lower back pain, Obesity, Type 2 diabetes and more
BioRestorative Therapies (NASDAQ:BRTX) is a fully integrated regenerative medicine company with preclinical and Phase 2 clinical programs focused on conditioning the bodies’ regenerative potential to treat major...
